Published on
November 19, 2025
In the media
Our lead oncology asset is nominated for Best Biomedical Product at Prix Galien Bridges Awards, recognizing its potential in advancing cancer therapeutics.
About 91±¬ÁϳÉÈËƬ Therapeutics
â€
91±¬ÁϳÉÈËƬ Therapeutics is a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.
â€
The company’s first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
â€
91±¬ÁϳÉÈËƬ’s oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. The company’s autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
â€
91±¬ÁϳÉÈËƬ is headquartered in Oxford, UK.
â€
More information: Website |
â€
Media enquiries
Patrick White, Head of Communications
â€
